for

Rapid Whole Blood Testing for Infectious Mononucleosis Antibodies

The Epstein Barr virus (EBV), which causes infectious mononucleosis (IM), is one of the most common human viruses. EBV occurs worldwide, and most people become infected with EBV sometime during their lives. In the United States, as many as 95 percent of adults between 35 and 40 years of age have been infected. In most developed countries, including the U.S., infection with EBV most often occu...

Bench-Top Centrifuges--Basic Tools for the Small Lab

No matter how elementary or advanced, every clinical laboratory possesses one essential devicea centrifuge. It may be a bench-top or floor model, refrigerated or non-cooled, but this apparatus, because of its unique ability to fractionate liquid specimens by creating spin-induced high g-forces, has long been a standard tool for both diagnosis and research applications. For all this utility, t...

Monitoring Options Expand for Therapeutic Agents and Drugs of Abuse

In keeping with the recent proliferation of rapid, easy-to-use diagnostic tests, many assays and collection products have entered the marketplace to help clinicians assess dosage appropriateness of therapeutic drugs and to screen for the presence of drugs of abuse. Some of these products require laboratory support while many simple test kits are suitable for point of care use by medical profe...

Testing for Human Papillomavirus

Human papillomaviruses (HPVs) are small, closed circle, double-stranded DNA viruses, which are classified by nucleic acid sequence homology rather than serologic reactivity. Genital HPVs are the most prevalent sexually transmitted pathogens. Of the approximately 50 anogenital HPVs, there are a limited number of high and intermediate risk types dete...

Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy

Contributing Editor With over 200,000 new cases and 40,000 deaths per year, breast cancer undoubtedly qualifies as one of Americas most serious health problems. Recently, efforts to develop early detection methods and more effective therapy have made important progress. This is particularly...

Avian (Bird) Flu: Is There a Role for Rapid Tests?

With human infections of bird flu (avian influenza) reported in Asia and Eastern Europe, public health officials have moved swiftly to develop policies on surveillance, diagnosis, and treatment. The virus in question is the H5N1 subtype of influenza A, which has become epidemic...

New Quality Control Systems for Every Laboratory Application

Quality Control (QC) materials and procedures are key to meeting the needs of doctors and patients by verifying accuracy and precision of analytical methods. Vendors of these systems can be a valuable resource, designing customized QC materials and protocols to help lab managers ensure that analytical error st...

Managing Preanalytical Processes for Patient Safety

Contributing Editor Positive patient identification (ID) is a major put by healthcare accrediting bodies for the past few years. Until recently, the costs associated with hardware and software were beyond the reach of the average hospital or laboratory. Today there are multiple vendors with devices that can be integra...

Non-Invasive Diagnostic Tests for Celiac Disease

Celiac disease (CD) is an autoimmune inflammatory disease of the small intestine that is triggered in genetically susceptible persons by the ingestion of the gluten-containing grains wheat, rye, barley, and possibly oats. The condition is thought to result from the activation of both a T-cell and B-cell immune respons...

Sygnis Pharma AG announces date for presentation of clinical results

HEIDELBERG, Germany, 11 July 2007 – On 23 July SYGNIS PharmaAG will present the results of the clinical phase IIa study forAX200 (AXIS-study). AX200, a compound for the treatment of stroke, is the mostadvanced drug candidate in SYGNIS’ product pipeline. Theprimary aim of the study is to show safety and tolerability ofAX200 in acute stroke patients. The results of the AXIS-stud...

Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis

RIDGEFIELD, Conn., July 11, 2007 /PRNewswire/ -- Phase 3 resultsfrom the RE-NOVATE(TM) trial demonstrated that oral dabigatranetexilate once daily, administered for an average of 33 days, wasnon-inferior to enoxaparin, also administered for an average of 33days, in preventing venous thromboembolism (VTE) and all-causemortality after total hip replacement surgery. In this trial, therate o...

BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Jul 11, 2007 - BioSantePharmaceuticals, Inc. (Amex: BPA) today announced new positiveresults demonstrating that its calcium phosphate (CaP)nanoparticle-based vaccine adjuvant, BioVant(TM), may serve as aneffective vaccine adjuvant for the development of a dose sparingvaccine against H5N1 avian flu, widely known as bird flu. The new results are based on...

New Information on the Potential of Plasmin Shared at ISTH Congress

RESEARCH TRIANGLE PARK, N.C. & GENEVA--(BUSINESS WIRE)--Jul 11,2007 - New information representing the continuing research anddevelopment program for Plasmin (Human), TAL-05-00018, waspresented by Talecris Biotherapeutics, Inc.(http://www.talecris.com) this week at the XXIst InternationalSociety for Thrombosis and Haemostasis (ISTH) Congress in Geneva,Switzerland. The information includ...

Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy

Positive interim results prompt request for meeting with FDA SEATTLE, July 11, 2007 /PRNewswire-FirstCall/ -- CellTherapeutics, Inc. (CTI) announced today that interim results ofits phase II/III trial comparing CPOP-R, in which pixantrone issubstituted for doxorubicin in standard CHOP-R first-line treatmentof patients with aggressive non-Hodgkin's lymphoma (NHL), resultedin essentially al...

CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa

-- New Preclinical Information May Correlate with Clinical HbA1cReductions Observed in Phase 3 CARISA and MERLIN TIMI-36 ClinicalTrials -- PALO ALTO, Calif., July 9, 2007 /PRNewswire-FirstCall/ -- CVTherapeutics, Inc. announced today that researchers have completedpreliminary preclinical studies showing that ranolazine increasedglucose stimulated insulin secretion in pancreatic beta cells...

Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone

- Results Fail to Demonstrate Meaningful Placebo Adjusted WeightLoss; Obesity Program to be Discontinued NEW YORK, July 09, 2007 /PRNewswire-FirstCall/ -- ManhattanPharmaceuticals, Inc. today announced results of the company's twoPhase 2a clinical trials of oral Oleoyl-estrone (OE). The resultsof both randomized, double-blind, placebo-controlled studies, onein common obesity and the other...

AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease

PORTLAND, Ore.--(BUSINESS WIRE)--Jul 10, 2007 - AVI BioPharma, Inc.(Nasdaq:AVII) announced today that its partner Cook Medical hascompleted target patient enrollment and released six-monthfollow-up data from a Phase II clinical trial known as Appraisal.The trial, currently being held in Germany, was designed to studythe effect of the Neugene(R) antisense drug Resten-MP(TM), whenused in conj...

BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease

WAKEFIELD, Mass.--(BUSINESS WIRE)--Jul 10, 2007 - BusinessWeekpublished an article on July 6 discussing the race bypharmaceutical and biotechnology companies to be first to bring tomarket an effective angiogenesis treatment for cardiovasculardisease. While angiogenesis therapies are being pursued bySanofi-Aventis, Boston Scientific, Baxter, and Genzyme, amongothers, the article highlights a...

International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis

- ENDORSE Global Findings Highlight the Need to UrgentlyImplement Hospital-Wide Strategies to Optimize VTE Management:Systematically Assess Patient Risk for VTE and Provide Appropriateprophylaxis to Prevent VTE Venous thromboembolism (VTE) risk is high among hospitalpatients and most of these at-risk patients are not pro...

NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product

EAST WINDSOR, N.J.--(BUSINESS WIRE)--July 9, 2007 - NexMed, Inc.(NASDAQ: NEXM), a developer of innovative transdermal treatmentsbased on the NexACT(R) drug delivery technology, today announcedthat Novartis Pharma AG has completed patient enrollment for PhaseIII clinical trials for NM100060, a topical treatment foronychomycosis (nail fungus). Pursuant to the terms of the licensingagreement w...

AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis

AM Pharma Continues Its Success with Positive Phase IIa ClinicalTrial Results First clinical Results Confirm Potential New Application of KeyProduct in AM-Pharma's Pipeline BUNNIK, The Netherlands, July 9, 2007-AM-Pharma B.V., thebiopharmaceutical company developing novel therapeutics to treatinfectious and inflammatory diseases, today announced the positiveclinical results of its...

Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

Rivaroxaban, a New Oral, Once-Daily Direct Factor Xa Inhibitor,Shows a Significant Reduction in Deep Vein Thrombosis and PulmonaryEmbolism Compared with Enoxaparin with Similarly Low BleedingRates GENEVA, July 8, 2007 - Late-breaking Phase III clinical trialdata presented today at the XXI International Society on Thrombosisand Haemostasis (ISTH) Congress demonstrate that once-daily...

New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility

EXCLAIM is the First International Study to Show That ExtendedThromboprophylaxis Reduces VTE Risk in Acutely-ill Medical PatientsWith a Statistically Significant 44% PARIS, July 8, 2007 /PRNewswire-FirstCall/ --Sanofi-aventisannounced today the results of the EXCLAIM (EXtended CLinicalprophylaxis in Acutely Ill Medical patients) study, which showedthe benefit of extended prophylaxi...

Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

GENEVA--(BUSINESS WIRE)--Jul 8, 2007 - Late-breaking Phase IIIclinical trial data presented today at the XXI InternationalSociety on Thrombosis and Haemostasis (ISTH) Congress demonstratethat once-daily rivaroxaban achieved superior efficacy in theprevention of venous thromboembolism (VTE) in patients undergoingknee replacement surgery in a head-to-head comparison withenoxaparin, the curren...

TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment

LOD, Israel--(BUSINESS WIRE)--Jul 9, 2007 - TransPharma MedicalLtd., a specialty pharmaceutical company focused on the developmentand commercialization of drug products utilizing a proprietaryactive transdermal drug delivery technology, announced todaypromising results of its phase I clinical trials demonstrating thesafety and pharmacokinetic profile of its ViaDerm-hPTH (1-34)product for th...

Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology

LUGANO, Switzerland--(BUSINESS WIRE)--Jul 9, 2007 - ZIOPHARMOncology, Inc. (NASDAQ: ZIOP) announces that positive interim datafrom an ongoing phase II trial of ZIO-201 (isophosphoramide mustard- IPM) to treat advanced sarcoma patients was presented at theEuropean Society of Medical Oncology (ESMO) meeting held July 5-8,2007 in Lugano, Switzerland. The abstract entitled, "Phase-I/IIStudy of...

Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis

IRVINE, Calif.--(BUSINESS WIRE)--Jul 6, 2007 - Cobalis Corp.(OTCBB:CLSC), a pharmaceutical development company specializing inanti-allergy medications, today reported preliminary top-lineresults from two Phase III clinical trials for its drugPreHistin(TM) in patients with moderate to moderately severeseasonal allergic rhinitis, commonly known as hay fever. The trialsshowed very low symptom...

DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC

MIAMI, FL -- (MARKET WIRE) -- July 06, 2007 -- DOR BioPharma,Inc. (OTCBB: <a target="_blank" href='http://studio.financialcontent.com/Engine?Account=iwire&PageName=QUOTE&Ticker=DORB"%3EDORB'>http://studio.financialcontent.com/Engine?Account=iwire&PageName=QUOTE&Ticker=DORB">DORB )("DOR" or the "Company") announced today that the European PatentOffice has granted a paten...

BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease

WAKEFIELD, Mass.--(BUSINESS WIRE)--Jul 6, 2007 - BusinessWeek todaypublished an article discussing the race by pharmaceutical andbiotechnology companies to be first to bring to market an effectiveangiogenesis treatment for cardiovascular disease. Whileangiogenesis therapies are being pursued by Sanofi-Aventis, BostonScientific, Baxter, and Genzyme, among others, the articlehighlights a very...

Stanford Researchers Find Brain Pathway of Depression in Rats

STANFORD, Calif.--(BUSINESS WIRE)--Jul 5, 2007 - Scientists' huntfor the cause of depression has implicated so many suspects andfound so many treatments with different mechanisms that thecondition remains an enigma. Now researchers at the StanfordUniversity School of Medicine have identified one unifyingprinciple that could explain how a range of causes and treatmentsfor depression converge...

Peer Reviewed Journal Article Indicates Repros' Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jul 5, 2007 - ReprosTherapeutics Inc. (NasdaqGM:RPRX) today announced that an articlehas been published in the July 1, 2007 issue of Oncology Reportsindicating a potential for a new approach to the treatment ofbreast cancer using Proellex. The article reviews the findings froma study conducted in an accepted in vivo rat model of breastcancer. The study...

Skin Rash Actually Signifies Better Outcomes for Pancreatic and Lung Cancer Patients

PHILADELPHIA, July 3, 2007-- – The appearance of arash in cancer patients treated with erlotinib (Tarceva) isstrongly associated with longer survival, according to researchersfrom the drug’s developer, OSI Pharmaceuticals, Inc. This isnot the first time that rash has been associated with a survivaladvantage with EGFR inhibitors – a class of drugs whichincludes erlotinib...

Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease

- Publication of New Cardiovascular Target from Lexicon's GeneticResearch - THE WOODLANDS, Texas, July 02, 2007 /PRNewswire-FirstCall/ --Lexicon Pharmaceuticals, Inc. today reported results frompreclinical research demonstrating that antibodies directed to apotential new target, angiopoietin-like protein 4 (ANGPTL4),rapidly lower triglycerides and cholesterol. Research suggests thata mon...

Researchers Discover Method for Identifying How Cancer Evades the Immune System

PHILADELPHIA, July 3, 2007-- One of the fundamental traits of atumor – how it avoids the immune system – might becomeits greatest vulnerability, according to researchers from theUniversity of Southern California. Their findings,demonstrated in human breast and colorectal cancers, indicate thata technique for determining a tumor’s “immunesignature,” could be...

Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease

Adult stem cells cultivated from patients' own blood canpotentially improve the quality of life for patients whose lowerextremities are affected by peripheral vascular disease, accordingto a study in China. SHENZHEN, China, July 02, 2007 /PRNewswire/ -- BeikeBiotechnology Co., Ltd. (<a target="_blank" href="http://www.beikebiotech.com/">http://www.beikebiotech.com )today announced tha...

Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers

WASHINGTON, January 29, 2007 /PRNewswire-USNewswire/ -- RearAdmiral Timothy Ziemer (U.S. Navy, retired), the President'sMalaria Coordinator, announced his intent to name Dr. BernardNahlen to serve as Deputy Coordinator of the President's MalariaInitiative (PMI). Dr. Nahlen is a Commissioned Officer in the U.S.Public Heath Service and has most recently served as SeniorAdvisor, Monitoring...

Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee

- Pain Reductions Observed at Eight Weeks Sustained up to 12 Weeksand Drug Remains Very Well Tolerated - SOUTH SAN FRANCISCO, Calif., July 02, 2007/PRNewswire-FirstCall/ -- Anesiva, Inc. today announced preliminarylonger-term, follow-up results from a Phase 2 study showing that a1mg treatment with Adlea(TM) (formerly 4975) in patients withmoderate-to-severe osteoarthritis of the knee prod...

Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections

DENVER--(BUSINESS WIRE)--Jul 2, 2007 - Ceragenix Pharmaceuticals,Inc. (OTCBB:CGXP), a biopharmaceutical company focused oninfectious disease and dermatology, today announced thatresearchers at the University of Pennsylvania led by Dr. PaulJanmey and Dr. Robert Bucki, in collaboration with Dr. Paul B.Savage of Brigham Young University, have demonstrated in a seriesof in vitro experiments tha...

Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival

- New Data from Phase III Intergroupe Francophone du Myelome (IFM)Trial Presented During IMW - CAMBRIDGE, Mass., July 02, 2007 /PRNewswire-FirstCall/ --Millennium Pharmaceuticals, Inc. today reported that new data werepresented on the comparative Phase III clinical trial evaluating aVELCADE based therapy in newly diagnosed multiple myeloma (MM)patients. As induction therapy prior to stem...

Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis

LONDON, 2 July2007: Chi-Med, the Hutchison Whampoa backed pharmaceutical andhealthcare Group, today announces positive results for its Phase IIproof-of-concept study...